
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 23, 2023, titled "Glenmark Pharmaceuticals receives ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005% 0.064%".
Filed with NSE · · 3 pages · English
Watch Glenmark Pharmaceuticals' latest callGlenmark Pharmaceuticals (NSE:GLENMARK) Q2 2026 Earnings Call · Replay · Nov 6Read the transcript of Glenmark Pharmaceuticals (NSE:GLENMARK) Q2 2026 Earnings Call
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 23, 2023, titled "Glenmark Pharmaceuticals receives ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005% 0.064%".
Glenmark Pharmaceuticals Limited on 6ix
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals